preceding RFA to Atezo+Bev for HCC patients

Recruiting

• Conditions: hepatocellular carcinoma

• Registration Number: jRCT1041200075

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-12-15
• Study Start: 2021-01-18
• Last Update Posted: 2025-02-27

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent

Exclusion Criteria

refractory ascites or pleural effusion; unsuitable for RFA, risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate

Study & Design

• Study Type: Interventional
• Study Design: parallel assignment

Primary Outcome Measures

Name	Time	Method
-		Progression-free survival